Key Highlights

● Amgen closed at $447.28 on October 22 as health care hit a record high.

● The biotechnology company had no company-specific news.

● Moderna's slide did not derail the sector's record.

● Nasdaq decliners outnumbered advancers by 1.37-to-1.

Amgen (NASDAQ:AMGN) gained on Thursday, October 22, 2026, closing at $447.28 and adding to a firm day for health care stocks on the Dow Jones Industrial Average.

The biotechnology company had no company-specific news. Its advance reflected a broad rotation into health care, a sector that hit a record high even as technology shares suffered a punishing selloff.

Health care as a hiding place

Amgen makes medicines for conditions ranging from heart disease and osteoporosis to cancer and inflammatory disorders. Sales of established drugs like these tend to be relatively insensitive to the economic cycle, and that steadiness drew buyers on a day when investors were questioning the economics of the AI boom.

Health care's record came despite a heavy drag from Moderna (NASDAQ:MRNA), one of the weakest performers in the S&P 500. Moderna's shares fell after data from its Phase 3 melanoma vaccine trial with Merck (NYSE:MRK) reportedly leaked before its scheduled presentation. A UBS analyst described the results as "solid data" and the stock's reaction as a "sell the news" event. Amgen and Johnson & Johnson (NYSE:JNJ) helped offset Moderna's decline within the sector.

The selloff that drove the shift

The catalyst for the rotation came from the tech world. Meta Platforms (NASDAQ:META) reported late Wednesday that it had narrowed its 2026 capital-spending range to $135 billion to $145 billion, and its free cash flow turned negative at $2.12 billion, the first cash outflow in more than a decade, according to market data. Lam Research (NASDAQ:LRCX)'s outlook cited supply constraints, and Nvidia (NASDAQ:NVDA)'s chief executive warned about the scarcity of capital for AI cloud providers.

The Nasdaq Composite, where Amgen is listed, fell 694.00 points, its steepest drop since June 5. The S&P 500 lost 93.74 points to 7,663.43, its worst day since July. Yet about two of every three S&P 500 stocks rose, according to market reports, a sign that money was moving rather than leaving.

Nasdaq-listed Amgen was a rare bright spot on that exchange. Decliners outnumbered advancers on the Nasdaq by 1.37-to-1, according to market data, and the exchange logged 342 new lows against 82 new highs.

The Dow's defensive cushion

On the Dow Jones Industrial Average, defensive names did the heavy lifting. Procter & Gamble (NYSE:PG) posted its best day since March 2020, and Home Depot (NYSE:HD), Johnson & Johnson, Verizon (NYSE:VZ), Coca-Cola (NYSE:KO) and McDonald's (NYSE:MCD) all rose. The blue-chip average ended up 11.89 points at 52,867.98, essentially flat and at a one-month high, according to market data.

Falling Treasury yields added support. The 10-year yield closed back below a closely watched threshold for the first time since September 22. Lower yields can make steady earners such as large drugmakers more attractive relative to bonds.

Consumer staples also had a banner session, posting their best day since April 2025 and closing at a record. Utilities and financials rose as well.

Amgen Watches Moderna's ESMO Data

Health care investors will turn to Saturday's full presentation of Moderna and Merck's melanoma vaccine data at the ESMO conference in Madrid, which could shape sentiment across biotech. The Federal Reserve's policy decision on October 28, and earnings from Microsoft (NASDAQ:MSFT), Alphabet (NASDAQ:GOOGL) and Amazon (NASDAQ:AMZN) next week, will show whether the rotation into defensive sectors continues.